What is the core difference between ipamorelin and tesamorelin?
Both peptides aim to raise the body's own growth hormone (GH) rather than inject GH directly, but they pull different levers. Tesamorelin is an analog of growth-hormone-releasing hormone (GHRH) — the natural hormone the hypothalamus uses to tell the pituitary to make and release GH. It binds the GHRH receptor, so it works through the upstream, physiologic pathway. Ipamorelin works through a separate door: it activates the ghrelin receptor (GHS-R1a), the same receptor the "hunger hormone" ghrelin uses, which also drives a GH pulse.
The much bigger difference today is regulatory. Tesamorelin is an FDA-approved medicine, sold as Egrifta — but it is approved only for one narrow use: reducing excess visceral abdominal fat in people with HIV who have lipodystrophy. Ipamorelin has no FDA approval for any indication. So while these two are often discussed side-by-side as "GH peptides," only one of them is an approved drug, and even that one is approved for a specific population, not for general fat loss or anti-aging.
What does the human evidence actually show?
Tesamorelin has the stronger evidence base because it went through full FDA trials. In a pivotal Phase 3 randomized trial in people with HIV-associated abdominal fat accumulation, visceral adipose tissue fell by about 15.2% on tesamorelin versus a 5.0% increase on placebo over 26 weeks, alongside improvements in some lipid measures (Falutz, NEJM 2007). That data is what supports its approved HIV indication — and it is worth stressing that the trials were done in that specific population, not in healthy adults seeking body recomposition.
Ipamorelin's human record is much thinner. It is well characterized in the lab as the "first selective" GH secretagogue (Raun, 1998), meaning it raised GH in early studies without strongly raising cortisol or prolactin. But its most substantial human trial — a Phase 2 randomized, placebo-controlled study for postoperative ileus after bowel surgery — did not meet its primary endpoint (Beck, 2014), and development for that use was discontinued. There is no completed human trial demonstrating efficacy for the GH-related, fat-loss, or "anti-aging" purposes it is often marketed toward.
How do the mechanisms and effects differ?
Because tesamorelin acts at the GHRH receptor, it is designed to amplify the body's normal GH rhythm; the molecule is built to resist the DPP-IV enzyme so it lasts long enough to be useful. Its documented effect in trials is a selective reduction in visceral (deep abdominal) fat in the HIV population studied — not subcutaneous fat broadly, and not muscle gain.
Ipamorelin, as a ghrelin-receptor agonist, mimics ghrelin's GH-releasing signal. Its selling point in the literature is selectivity — in early studies it raised GH with comparatively little effect on cortisol, prolactin, or appetite relative to older secretagogues like GHRP-6. But "selective in a lab assay" is not the same as "proven to produce a meaningful clinical outcome in people," and that clinical outcome data does not exist for ipamorelin. The two are sometimes discussed as complementary (GHRH-pathway plus ghrelin-pathway), but combining unapproved or off-label peptides is not supported by controlled human evidence and carries unknown risk.
Are they legal, approved, and allowed in sport?
Tesamorelin is a legal, FDA-approved prescription medicine within its indication — HIV-associated lipodystrophy. Using it for general weight loss, body composition, or longevity is off-label, meaning it falls outside what the FDA reviewed and approved; that is a decision only a licensed clinician should weigh. Ipamorelin is not FDA-approved for anything, and its availability through compounding pharmacies has been contested: the FDA placed it on the Category-2 portion of its interim 503A bulk-substances list in 2023 (the tier flagged for significant safety questions), a status that has since been the subject of nomination withdrawals and ongoing review.
For anyone in drug-tested sport, the answer is simpler and stricter: both are banned. The World Anti-Doping Agency prohibits GHRH analogs such as tesamorelin and GH secretagogues such as ipamorelin at all times under Section S2 of its Prohibited List. A positive test for either is an anti-doping rule violation, in or out of competition.
Tracking either compound on PeptidePanel
If a clinician has prescribed tesamorelin within its approved use, the day-to-day work is monitoring: logging doses, tracking the biomarkers that matter (IGF-1, glucose and HbA1c, lipids, waist measurements), and catching side effects early. PeptidePanel is a neutral tracking layer for exactly that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
PeptidePanel does not sell, source, supply, or prescribe any compound, and nothing here is medical advice. Ipamorelin in particular is unapproved with unproven human efficacy, and any use of either peptide is a decision to make only with a qualified prescriber who understands the risks and your individual situation.